

Ref: FOI/GS/ID 6133

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

29 October 2020

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to cancer treatments.

You asked:

- 1. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma)?*
- 2. Of these patients how many are locally advanced, recurrent, metastatic and unresectable head and neck cancer patients?*
 - a. Locally advanced*
 - b. Recurrent*
 - c. Metastatic*
 - d. Unresectable*
 - e. Unknown*
- 3. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma) with the following agents?*
 - a. Carboplatin (only or in combination with 5-FU)*
 - b. Cisplatin (only or in combination with 5-FU)*
 - c. Cetuximab with/without chemotherapy*
 - d. Cetuximab with radiotherapy*
 - e. Pembrolizumab monotherapy*
 - f. Pembrolizumab with chemotherapy*
 - g. Nivolumab*
 - h. Docetaxel (only or in combination with 5-FU)*
 - i. Fluorouracil (5FU)*
 - j. Radiotherapy only*
 - k. Other*
- 3b. Does your health trust participate in any ongoing clinical trials for the treatment of head and neck cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?*

4. Within your health trust how many patients have been treated in the past 6 months with the following agent for colorectal cancer [CRC];

- a. Afibercept
- b. Bevacizumab
- c. Capecitabine
- d. CAPIRI
- e. CAPOX
- f. Cetuximab not in combination with FOLFIRI or FOLFOX
- g. Cetuximab in combination with FOLFIRI
- h. Cetuximab in combination with FOLFOX
- i. Irinotecan
- j. FOLFIRI
- k. FOLFOX
- l. Oxaliplatin
- m. Panitumumab not in combination with FOLFIRI or FOLFOX
- n. Panitumumab in combination with FOLFIRI
- o. Panitumumab in combination with FOLFOX
- p. Nivolumab
- q. Raltitrexed
- r. Ramucirumab
- s. Regorafenib
- t. Sorafenib
- u. 5FU only
- v. Tegafur Uracil + 5FU
- w. Trifluridine–tipiracil
- x. XELOX
- y. Other

5. Within your health trust how many patients have been treated in the past 6 months with the following agent for Renal Cell Carcinoma:

- a. Sunitinib
- b. Avelumab + Axitinib
- c. Axinitib
- d. Cabozantinib
- e. Everolimus
- f. Lenvantinib + Everolimus
- g. Nivolumab
- h. Nivolumab + Ipilimumab
- i. Pazopanib
- j. Pembrolizumab + Axitinib
- k. Sunitinib
- l. Temsirolimus
- m. Tivozanib

5b. Does your health trust participate in any ongoing clinical trials for the treatment of renal cell cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?

Trust response:

- 1. 95
- 2.
- a. 1

- b. 1
- c. 1
- d. 0
- e. 92
- 3.
- a. 8
- b. 4
- c. 0
- d. 0
- e. 0
- f. 0
- g. 2
- h. 2
- i. 4
- j. 64
- k. 4

3b. I have been unable to obtain this information. If you still require this data can you please let me know and I will endeavour to respond.

- 4.
- a. 93
- b. 0
- c. 0
- d. 21
- e. 6
- f. 0
- g. 0
- h. 5
- i. 1
- j. 0
- k. 14
- l. 8
- m. 0
- n. 0
- o. 0
- p. 0
- q. 3
- r. 1
- s. 0
- t. 0
- u. 0
- v. 1
- w. 0
- x. 6
- y. 0
- 5.
- a. 110
- b. 0
- c. 1
- d. 1
- e. 0

- f. 0
- g. 0
- h. 1
- i. 1
- j. 0
- k. 1
- l. 0
- m. 0

5b. I have been unable to obtain this information. If you still require this data can you please let me know and I will endeavour to respond.